Please ensure Javascript is enabled for purposes of website accessibility

Why Doesn’t MannKind Have a Partner?

By Max Macaluso - Updated Apr 7, 2017 at 12:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biotech company MannKind (MNKD -2.85%) is developing a fast-acting, inhalable insulin drug called Afrezza. The drug has previously been rejected by the FDA, but the company looks determined to get this product to market. Today, MannKind announced that its two Phase 3 Afrezza clinical trials have completed patient enrollment, and this will help the company stay on track to file for FDA approval in Q3 of 2013. The company has shown interest in linking up with a larger company, but a partnership has been elusive. It could be that Pfizer's (PFE -0.15%) failed attempt to market Nektar Therapeutic's (NKTR 2.31%) inhalable insulin product, Exubera, has made other big pharma companies hesitant to enter this market.

In the following video, healthcare analysts Max Macaluso and David Williamson explain this news, its impact on the company's share price, and discuss why MannKind still hasn't announced a partnership with any of the major pharmaceutical companies.

Biotech stocks can be some of the riskiest on the stock market, and can rapidly increase in value after positive clinical trial results --- or crash in the face of bad news. However, biotech is not the only technology investors can profit from. The Motley Fool's new report The Only Stock You Need To Profit From the NEW Technology Revolution highlights a company recommended by Fool analysts that still has plenty of room left to grow. To get instant access to the name of this company transforming the IT industry, click here -- it's free.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.91 (-0.15%) $0.08
MannKind Corporation Stock Quote
MannKind Corporation
MNKD
$4.44 (-2.85%) $0.13
Nektar Therapeutics Stock Quote
Nektar Therapeutics
NKTR
$3.54 (2.31%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.